newly issued ordinary shares at the offering price of THB 2 per share to the existing shareholders of the company via a Rights Offering (RO) at an offering ratio of every 5 existing ordinary shares for 1
1,080mn newly issued shares through Private Placement to Plan B Media Public Company Limited (“PlanB”) at THB 1.4381 per share, totalling THB 1,553mn. After the acquisition takes place, PlanB will become
retained earnings as a result of the recent dividend payment in May. Financial Ratio Financial Ratio As of June 30, 2019 Liquidity Ratio (times) 27.80 Debt to Equity Ratio (times) 0.04 Return on Equity - ROE
recent dividend payment and net loss during the year. Financial Ratio Financial Ratio As of December 31, 2019 As of March 31, 2020 Liquidity Ratio (times) 23.97 12.15 Debt to Equity Ratio (times) 0.04 0.11
Company Limited pursuant to Share Pledge Agreement dated 18 May 2017. Conditions for the debt repayment between WPS and the Company The Company and affiliates will repa all of the unpaid debts which are
company had signed the Share Purchase Agreement (SPA) with Engie Global Development B.V. to purchase 69.11% shares of GLOW and to acquire the remaining shares of 30.89% through tender offer process. Subject
was Baht 1,753.73 million, slightly increased when comparing to as of December 31, 2016 equivalent to Baht 55.55 million. In this regard, the debt to equity ratio was 1.70 times. Shareholder’s Equity as
provision for liability (provision of claim expense). Moreover, the Debt to equity (D/E) ratio decreased from 1.12 times at 30 December 2017 to 0.64 times in quarter 3 of 2018, which is the lowest rate since
** (%) 10.77 10.79 4) Return on Assets ** (%) 8.41 8.53 5) EBITDA * (Million Baht) 2,340 2,611 6) EBITDA to Total Assets (%) 2.39 2.53 7) Debt to Equity Ratio (Times) 0.65 0.72 8) Debt Service Coverage Ratio
overseas assets • Net debt to equity ratio at the end of 2Q 2020 stood at 0.98x, an increase from 0.48x on 31 December 2019 2Q 2020 SIGNIFICANT EVENTS Impacts of Coronavirus Disease 2019 (COVID–19) COVID-19